cyrilzakka/clinical-trials huggingface dataset:
Acquisition and Retention of Motor Memories in Adults and Typically Developing Children

Our motor skills require motor memories without which our behavior is only reflexes and stereotypies. The way which these memories form in the human brain constitute therefore a major challenge for neuroscience research. Some a lot of evidence suggests that any new motor skills is acquired in the cerebellum and then persisted in the cortex. This vision seems however caricature, the formation of memories motor probably requiring complex remodeling of cortico-cerebellar networks. The MotorMemo project aspires to better understand this remodeling, by testing more specifically the hypothesis of cerebellar weakening and strengthening cortical as a substrate for the formation of motor memories. A longitudinal study using a sensorimotor adaptation protocol, fMRI as well as a developmental perspective is proposed to verify this hypothesis.

A fundamental human faculty is that of adapting our motor behavior to changing environmental conditions. This faculty is comparable to an apprenticeship adaptive during which the individual updates, on a trial and error basis, the correspondence between sensory inputs and the resulting motor commands. Once updated, these correspondences or internal models allow the individual to produce a behavior precise and reproducible motor. The issue of model acquisition and retention internal movement is therefore central to our understanding of motor control. Relatedly, this question constitutes a gateway to a more comprehensive understanding of the mechanisms of learning and procedural memory.

The MotorMemo project therefore aims to study the formation of internal models of movement in the human brain, with the particularity of being interested in the correlates cerebral processes of acquiring and retaining an internal model of visuomotor transformation in healthy children (8-12 years) and adults.

Eligibility Criteria:
Inclusion Criteria:

* right-handed
* affiliated to a social security scheme
* who gave their consent to participate in the study

Exclusion Criteria:

* Contraindication to MRI
* visual impairment;
* suffering from one of the following pathologies:

  * dysphasia,
  * ADHD,
  * dyspraxia,
  * dyslexia,
  * dysorthography,
  * dyscalculia;
  * history of epilepsy
* subject in period of exclusion from another study,
* subject under administrative or judicial supervision
* pregnant or breastfeeding women
* Persons referred to in articles l1121-8
Role of Octreotide in Preventing Pancreatic Fistula After Pancreaticoduodenectomy (PD) in Patients With Soft Pancreas

This randomized controlled trial (RCT) aims at assessing the influence of octreotide on pancreatic fistula or complications following pancreatoduodenectomy in patients with soft pancreas. Previously reported trials have included all types of pancreatic resections and have include all types of pancreas and have shown no clearcut benefit of octreotide after pancreaticoduodenectomy (PD). Soft pancreas and normal sized duct are the risk factors for fistula following PD. This study's focus is on this select group of patients and aims to assess the role of octreotide in patients with soft pancreas.

Study design: Prospective open labeled randomized trial. AIM: Study aims at assessing the influence of octreotide on pancreatic fistula or complications following pancreatoduodenectomy in patients with soft pancreas.

Eligibility Criteria:
Inclusion Criteria:elective surgery patients undergoing pancreatoduodenectomy

* soft pancreas, no dilated duct

Exclusion Criteria:

* age \> 75 years old
* documented chronic pancreatitis
* previous pancreatic surgery
* previous gastric surgery vagotomy
* documented pancreatic duct dilatation
An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.

Study of what the body does to drug BMS-986165 when it is taken together with pyrimethamine


Eligibility Criteria:
Inclusion Criteria:

* Patients must be willing and able to complete all study-specific procedures and visits
* Healthy patients, as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiogram, and clinical laboratory determinations
* Body mass index (BMI) of 18 to 32 kg/m2, inclusive, at screening
* Normal renal function at screening

Exclusion Criteria:

* Any medical condition that presents a potential risk to the participant and/or may compromise the objectives of the study, including a history of or active liver disease
* Current or recent (within 3 months of study drug administration) gastrointestinal disease that could impact upon the absorption of study drug
* History or presence of clinically significant acute or chronic bacterial, fungal, or viral infection (eg, pneumonia, septicemia) within the 3 months prior to screening
* Additional criteria may apply
How Bleeding Affects Delirium in Older Patients With Hip Fractures: The IMPROVE-HIP Study

The goal of this clinical trial is to investigate whether early detection of bleeding and prompt blood transfusions can help prevent delirium in patients aged 75 and older who are admitted to the hospital with hip fractures. The main question the trial aims to answer is:

• Do patients aged 75 and older with hip fractures benefit from quicker treatment of anaemia (low blood count) to reduce the risk of delirium?

Researchers will compare early diagnosis and treatment of bleeding with standard care to determine if it helps lower the risk of developing delirium.

Participants will:

* Undergo blood tests and have their vital signs checked, as well as be screened for delirium three times a day for the first 48 hours after surgery.
* Receive blood transfusions promptly if their haemoglobin levels drop below a specified threshold.
* Have a follow-up visit at 30 days to assess their memory and overall quality of life.
* Have another follow-up at 90 days to check for hospital readmissions and survival


Eligibility Criteria:
Inclusion Criteria:

* Hip fracture

Exclusion Criteria:

* Pathological hip fracture
* Periprosthtic fracture
* Unable to speak or understand Danish
* Does not wish to recieve blood transfusion
* If the investigator finds the patient unable to cooperate to the study (e.g. in case of severe dementia and externalizing behaviour)
Field Randomization of Nerinetide (NA-1) Therapy in Early Responders

The purpose of this study is to determine whether nerinetide (NA-1) is effective in reducing global disability in patients with acute cerebral ischemia if administered early after symptom onset.

Nerinetide (NA-1) is being developed as an emergency drug aimed at reducing global disability in patients with acute cerebral ischemia if administered early after symptom onset.

The primary objective is to determine the efficacy of nerinetide in reducing global disability in patients with acute stroke. The secondary objectives are to determine the efficacy of nerinetide in reducing functional dependence, reducing mortality rate, reducing worsening of stroke, improving neurological outcome and improving activities of daily living.

The leading safety objectives are to determine the effect of administering a target dose of 2.60 mg/kg (up to a maximum dose of 270 mg) IV infusion of nerinetide within three hours of symptom onset by paramedics in the field on serious adverse events and 90-day mortality.

This trial is a multicenter, randomized, double-blind, placebo-controlled, single dose study initiated prehospital in the ambulance. It is being conducted using Emergency Medical Services (EMS) in Canada. Subjects with suspected acute stroke will be identified in the field by trained paramedics using the approved stroke protocol in use by the local EMS system, and further screened for eligibility and approval by an on-call trial physician. The paramedics will administer the study drug. Upon arrival at the emergency department, subjects will receive standard-of-care.

An Independent Data Monitoring Committee will perform safety reviews of the clinical data.

Eligibility Criteria:
Inclusion Criteria:

* Provisional diagnosis of acute stroke as identified by paramedics using the local stroke triage tool
* Respiratory rate 12-24 breaths per minute
* Oxygen saturation ≥ 90% on room air
* Systolic blood pressure \< 90 or \> 220 mmHg
* Weight 45-120 kg
* Last seen in usual state of health less than 3 hours before anticipated study drug initiation
* Independently ambulatory with or without devices prior to event
* LAMS score of 2-5 for at least 15 minutes and remains 2-5 at time of randomization

Exclusion Criteria:

* Lack of IV access
* Canadian Triage and Acuity Scale Level 1 and/or uncorrected airway, breathing or significant circulatory problem
* Blood sugar \< 3 mmol/L (\< 55 mg/dL)
* Seizure at onset of symptoms or observed by paramedic
* Glasgow coma score of \<10
* Major head trauma in the last three months
* Recent stroke in the last three months
* Known or presumptive signs of pregnancy or breastfeeding
* Prisoner
* Long term care facility resident
* Known advance directive to not resuscitate
* Known participation in a clinical trial with an investigational drug or device within 30 days preceding this trial
* Pre-existing neurologic, psychiatric, or advanced systemic condition that would preclude obtaining the neurological or functional outcome evaluations
Functional Rehabilitation With HUBER Platform in the Treatment of Non-specific Chronic Low Back Pain.

The objective of this study is to evaluate the effectiveness of centre-based program of 6 weeks with HUBER platform on the spine flexion-to-extension ratio at 60 and 120˚/s, pain and trunk flexibility in individuals with chronic low back pain (CLBP). A total of 70 individuals with Non-specific Chronic Low Back Pain will be randomised into 2 intervention arms (1:1 ratio) that will be blindly evaluated: 1/ standard rehabilitation group and 2/ HUBER rehabilitation group. Both programs are centre-based and will last 6 weeks, with 4 sessions of 2 hours each per week.

The prevalence of chronic low back pain (CLBP) is increasing with age and the prevalence of sedentary lifestyle. According to guidelines, non-pharmacological approaches such as exercise and physical therapy have been proposed in first line treatments along with psychological follow-up and pain medication if needed. The physiotherapy, used in a comprehensive CLBP rehabilitation program, aims to decrease chronic pain and promotes proprioceptive and postural work, as well as spinal mobility, flexibility and muscle strengthening of the spinal area. Isokinetic concentric strength assessment at 60 and 120˚/s is one of the most commonly used criteria to examine the trunk flexors and extensors muscles strength. The objective of this study is therefore to evaluate the effectiveness of an intensive care program with HUBER platform on the spine flexion-to-extension ratio at 60 and 120˚/s measured by Cybex, pain and trunk flexibility in individuals with non-specific CLBP. A total of 70 individuals with CLBP will be randomised into 2 intervention arms (1:1 ratio) that will be blindly evaluated: 1/ standard rehabilitation group and 2/ HUBER rehabilitation group. Both programs are centre-based and will last 6 weeks, with 4 sessions of 2 hours each per week. All the sessions will be supervised by a physiotherapist and will include 1h of physiotherapy, 30min of balneotherapy and 30min of exercise on cycloergometer for the standard rehabilitation group or 30min of exercise on the HUBER platform for the HUBER group. All patients included will benefit from medical monitoring, evaluations and the rehabilitation program set up at the Clinique de Tréboul, Douarnenez, France.

Eligibility Criteria:
Inclusion Criteria:

* people aged between 20 - 55 years old
* with non-specific chronic low back pain (over 3 months)
* with clinical and radiological assessment.

Exclusion Criteria:

* chronic low back pain of specific etiology (trauma, tumor, inflammatory or infectious disease, and radicular syndrome)
* spine with major anatomical deformations
* any contraindication for the rehabilitation program
* surgery less than 3 months and/or receiving treatment with corticosteroids.
Genomics and Prognosis in GI Cancers

This study aims to collect biospecimens and explore the correlation of genomics and prognosis in alimentary tract cancers.

In this study, the investigators will collect clinical specimens of alimentary tract cancers and perform DNA and RNA analysis to identify genetic alterations for the development of a comprehensive somatic mutation databases and investigate their potential correlation with clinical, radiological and pathological variables. The genomics study included but not limited to target gene panel sequencing, whole exome sequencing, whole genome sequencing, bulk RNA sequencing, single cell RNA sequencing and metagenomics.

Eligibility Criteria:
Inclusion Criteria:

* Able to sign the informed consent
* Age \>= 20
* Histology proved pancreatic cancer, esophageal cancer, gastric cancer, hepatocellular carcinoma, cholangiocarcinoma, colorectal cancer
* Agree to provide tumor/normal tissue including but not limited to surgical specimen, biopsy, cytology specimen, bile, urine or stool
* Agree to receive blood sampling 20ml at first time and 10ml during each follow-up (total sampling amount no more than 30ml per month)

Exclusion Criteria:

* Cannot cooperate with blood sampling
Prospective Tolerability Assessment of a Probiotic Dietary Supplement

The dietary supplement being investigated is a formula containing a combination of eight probiotic strains. The combination formula was developed to support general gastrointestinal and immune health. Each of the strains in the formula have previously been studied in human subjects, including several clinical populations. However, the present eight strain combination formula has not previously been evaluated in human subjects. This prospective study will evaluate the tolerability of the eight strain formula in healthy adults.

Background \& Significance:

The dietary supplement being investigated is a formula containing a combination of eight probiotic strains. The combination formula was developed to support general gastrointestinal and immune health. Each of the strains in the formula have previously been studied in human subjects, including several clinical populations. However, the present eight strain combination formula has not previously been evaluated in human subjects.

Research Design \& Methods:

This prospective study will evaluate the tolerability of the eight strain formula in healthy adults over a 10-day period. The primary aim of the study is to assess tolerability as determined by the frequency of study participants who withdraw from the study due to adverse events.

Eligibility Criteria:
Inclusion Criteria:

- Age 21-75 years

Exclusion Criteria:

* Currently taking a probiotic, prebiotic, or fiber supplement (or they were taken within 10 days prior to screening)
* Currently taking antibiotic, antiparasitic, or antifungal medications orally or intravenously (or they were taken within 28 days prior to screening)
* Currently taking any supplements or medications impacting gastrointestinal motility
* Active gastrointestinal infection
* Current or previous history of chronic bowel disease
* Current or previous history of liver disease
* Current or previous history of chronic kidney disease
* History of gastrointestinal surgery
* A major medical or surgical event requiring hospitalization within 3 months prior to screening
* Current or previous history of cardiovascular disease
* Current or previous history of pre-Diabetes, diabetes mellitus, or hypoglycemia
* Known infection with human immunodeficiency virus, tuberculosis, hepatitis B or hepatitis C
* Genitourinary bacterial infections within 28 days prior to screening
* Current or previous history of seizure disorder
* Current or previous history of psychiatric illness
* History of alcoholism
* Cancer within the last 5 years
* Smoking or use of nicotine containing products within 28 days prior to screening
* Use of drugs of abuse and recreational drugs/substances within 12 months prior to screening
* Known intolerance or allergy to ingredients in the study supplement
* Women who are lactating, pregnant or planning pregnancy within the next two months
* Currently participating in another interventional research study or participated in another interventional study within 28 days prior to screening
Assessment of Video Assisted Thoracoscopic Surgery (VATS) Versus Open Surgery for Patients Undergoing Lobectomy

Assessment of VATS versus standard open surgery for treatment of non small cell lung cancer.


Eligibility Criteria:
Inclusion Criteria:

* Subject must be 18 years of age or older.
* Subject must have been clinically diagnosed with stage I to stage IIA non small cell lung cancer measuring and judged to be resectable.
* Subject must be able to tolerate general anesthesia, and have cardiopulmonary reserve to tolerate a lobectomy

Exclusion Criteria:

* Subject is pregnant (documented by pregnancy test) or breastfeeding.
* Subject has other severe illnesses that would preclude surgery such as

  * Unstable angina
  * Myocardial Infarction within 3 months
  * Coronary Artery Bypass Graft Surgery
* Subject has other active cancers
* Subject is unable to comply with any of the following:

  * Study requirements
  * Give valid informed consent
  * Follow-up schedule
Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms

This is an open-label extension study of another study protocol, MCS-2-TWN-a. Subjects who have completed the 12-week treatment and procedures under the protocol MCS-2-TWN-a will be eligible for this study.

This open-label extension study is designed to further assess the long-term safety and efficacy of MCS-2. Subjects who have completed the 12-week treatment and procedures under the protocol MCS-2-TWN-a will be eligible for another 40 weeks of MCS-2 treatment at the same daily dosage as the active treatment given under the protocol MCS-2-TWN-a. Subjects are limited to those who are currently not being treated medically for BPH or LUTS.

Eligibility Criteria:
Inclusion Criteria:

* Subject has completed 12 weeks of treatment under the protocol MCS-2-TWN-a.
* Subject is able to understand and willing to conform to the study procedures and has signed the informed consent form for participation in this extension study.

Exclusion Criteria:

* Subject has severe LUTS at the last visit under the protocol MCS-2-TWN-a.
* Subject is considered ineligible for the study by the investigator(s).
Experience in Being With Advanced Heart Failure Patients

The purpose of this study is to explore the experience in being with advanced Heart failure patients.

The aim is to explore the experience of advanced Heart failure patients during the disease trajectory in Taiwan.

Eligibility Criteria:
Inclusion criteria:

* the patients' conscious must be clear,
* vital sign is stable,
* and can communicate in Mandarin Chinese or Taiwanese.

exclusion criteria:

* consciousness is unclear
* and can't have effective communication to interviewer.
* the patient reject to join this study.
Analysis of Sleep Study Data to Assess Depressive Burden

This study evaluates the effectiveness of the MEB-001 device in assessing physiological parameters that provide a clinically significant depressive burden screener. This study uses objective physiological markers from MEB-001 to estimate the clinically significant depressive burden as subjectively reported by the subject with the Beck Depression Inventory - II (BDI-II).

This study evaluates the effectiveness of the MEB-001 device in assessing physiological parameters that provide a clinically significant depressive burden screener. This study uses objective physiological markers from MEB-001 to estimate the clinically significant depressive burden as subjectively reported by the subject with the BDI-II.

This is a two (2)-phase, non-significant risk, cross-sectional, naturalistic, single-arm, multi-center study conducted under a common protocol and designed to:

Phase 1: MEB-001 algorithm development (software medical device). Phase 2: Evaluate the effectiveness of the MEB-001 device in assessing physiological parameters that provide clinically significant depressive burden screener.

Eligibility Criteria:
Inclusion Criteria:

* Subject is age ≥18 years and ≤75 years.
* Subject is willing and able to provide consent.
* Subject has the ability to read and understand the instructions for the study.
* Subject is willing to adhere to study procedures.
* Subject is willing to undergo full night PSG study, as prescribed.

Exclusion Criteria:

* Subject has a pacemaker.
* Subject is suspected or known to have active alcohol or drug abuse (including but not limited to abuse of marijuana).
Activating Treatment as Prevention Through Community Mobilization in South Africa

The purpose of this study is to evaluate the impact of a community mobilization intervention on the uptake of HIV testing, linkage to and retention in HIV care using a community, cluster randomized trial.

Eight of 16 intervention naïve communities in the Agincourt HDSS will be randomized to receive the CM intervention to activate TasP based on the investigators CM conceptual framework. The 16 villages will be randomized based on the "restricted randomization" approach, a stratification method to ensure overall balance between intervention and control communities.

Intervention activities will map onto the investigators six mobilization domains identified in the investigators preliminary work as key components for communities to mobilize for change around HIV prevention. These activities will support communities to: 1) identify a shared concern around testing, linkage and retention in care; 2) enable communities to develop critical consciousness around TasP; 3) facilitate identification and development of structures and networks to disseminate information and activities around TasP; 4) identify and engage community leadership around TasP; 5) take collection action to support TasP; and 6) build community cohesion to address the HIV epidemic and support access to care.

The investigators will evaluate the impact of the intervention using a linked data set including electronic clinic records and the HDSS census data, which will allow us to determine whether people in the intervention communities test at higher proportions than those in control communities, whether individuals who test positive in the intervention communities are more likely to receive CD4 testing and initiate treatment within 3 months than the control communities, and whether those who are eligible and not eligible for treatment are retained in care.

The investigators will implement a representative cross-sectional survey in all 16 villages prior to and following the intervention in order to examine changes in CM domains across villages and the mechanisms through which the intervention affects HIV testing, linkage and retention.

In addition, intervention progress and dosage will be carefully monitored through a tracking system to document all workshops and activities that are carried out in each village.

Eligibility Criteria:
Inclusion Criteria:

* lived in the study area for 12 months
* age 18-49 years
* able to provide informed consent.

Exclusion Criteria:

-